WallStSmart

Aurora Cannabis Inc (ACB)vsHaleon plc (HLN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Haleon plc generates 2856% more annual revenue ($11.03B vs $373.12M). HLN leads profitability with a 15.1% profit margin vs -22.5%. HLN earns a higher WallStSmart Score of 58/100 (C).

ACB

Avoid

34

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -7.92

HLN

Buy

58

out of 100

Grade: C

Growth: 5.3Profit: 7.0Value: 10.0Quality: 6.5
Piotroski: 5/9Altman Z: 2.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ACB.

HLNUndervalued (+51.3%)

Margin of Safety

+51.3%

Fair Value

$22.93

Current Price

$9.74

$13.19 discount

UndervaluedFair: $22.93Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACB2 strengths · Avg: 9.5/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

HLN3 strengths · Avg: 8.7/10
EPS GrowthGrowth
92.0%10/10

Earnings expanding 92.0% YoY

Operating MarginProfitability
23.2%8/10

Strong operational efficiency at 23.2%

Free Cash FlowQuality
$1.26B8/10

Generating 1.3B in free cash flow

Areas to Watch

ACB4 concerns · Avg: 2.5/10
Market CapQuality
$184.87M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
2.3%3/10

Operating margin of 2.3%

Return on EquityProfitability
-15.5%2/10

ROE of -15.5% — below average capital efficiency

EPS GrowthGrowth
-94.7%2/10

Earnings declined 94.7%

HLN2 concerns · Avg: 4.0/10
PEG RatioValuation
2.354/10

Expensive relative to growth rate

Revenue GrowthGrowth
0.6%4/10

0.6% revenue growth

Comparative Analysis Report

WallStSmart Research

Bull Case : ACB

The strongest argument for ACB centers on Price/Book, Debt/Equity.

Bull Case : HLN

The strongest argument for HLN centers on EPS Growth, Operating Margin, Free Cash Flow. Profitability is solid with margins at 15.1% and operating margin at 23.2%.

Bear Case : ACB

The primary concerns for ACB are Market Cap, Operating Margin, Return on Equity.

Bear Case : HLN

The primary concerns for HLN are PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

ACB profiles as a turnaround stock while HLN is a value play — different risk/reward profiles.

ACB carries more volatility with a beta of 1.30 — expect wider price swings.

ACB is growing revenue faster at 6.8% — sustainability is the question.

HLN generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

HLN scores higher overall (58/100 vs 34/100), backed by strong 15.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aurora Cannabis Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Aurora Cannabis Inc. produces and distributes medical cannabis products globally. The company is headquartered in Edmonton, Canada.

Haleon plc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Haleon plc (HLN) is a leading global consumer health company focused on delivering innovative health solutions across critical segments including oral care, pain relief, respiratory health, and dietary supplements. Formed from the spin-off of GlaxoSmithKline, Haleon boasts a strong portfolio of well-established brands, such as Sensodyne, Panadol, and Voltaren, solidifying its presence in the lucrative consumer health market. With a commitment to sustainability and consumer-driven innovation, the company is well-positioned to enhance health outcomes on a global scale while driving growth and delivering shareholder value through strategic investments and product advancements.

Visit Website →

Want to dig deeper into these stocks?